Helix BioPharma (TSE:HBP) Stock Price Passes Below Two Hundred Day Moving Average - What's Next?

Key Points

• Helix BioPharma shares fell below their 200-day moving average in Thursday trading, dropping as low as C$1.60 and last changing hands at C$1.64. The stock’s 200-day moving average is C$2.07.
• The company has a market capitalization of about C$125.26 million and is trading with a negative P/E ratio of -27.33. It also has a debt-to-equity ratio of 2.34, a quick ratio of 1.04, and a current ratio of 0.04.
• Helix BioPharma is an oncology-focused company centered on its clinical-stage drug candidate L-DOS47, which has completed Phase Ib studies in non-small cell lung cancer. The company is also developing next-generation CEACAM6-targeting bi-specific ADCs.

Shares of Helix BioPharma Corp. (TSE:HBP - ) crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of C$2.07 and traded as low as C$1.60. Helix BioPharma shares last traded at C$1.64, with a volume of 21,111 shares.

Helix BioPharma Price Performance

The firm has a market capitalization of C$125.26 million, a P/E ratio of -27.33 and a beta of 0.40. The business has a fifty day moving average of C$1.89 and a 200-day moving average of C$2.07. The company has a debt-to-equity ratio of 2.34, a quick ratio of 1.04 and a current ratio of 0.04.

About Helix BioPharma

Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today's hardest-to-treat cancers. The Company's pipeline is led by Tumor Defense Breaker¿ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today's front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix's next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.